BridgeBio Pharma BBIO
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 1st percentile, 5-year average -9.9x
Below its usual level · 22nd percentile, 5-year average -4.1x
Near the bottom of its 5-year range · 6th percentile, 5-year average 126.3x
#4696 of 5161 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | -5.69 | – | -4.10 | 22% (cheaper than usual) | – |
| PE | -25.09 | -38.67 | -9.90 | 1% (cheaper than usual) | – |
| PS | 15.66 | 10.08 | 126.34 | 6% (cheaper than usual) | #4696 of 5161 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on BBIO.
Sign in to join the discussion.